Skip to main content
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. — Investor Relations & Filings

Ticker · OTLK ISIN · US69012T3059 LEI · 5493007AWUJ6HPMCBH11 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2025-10-03 Director's Dealing
Country US United States of America
Listing US OTLK

About Outlook Therapeutics, Inc.

https://outlooktherapeutics.com/

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of therapies for ophthalmic indications. The company's lead product candidate is ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of retinal diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). If approved in the United States, it would be the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications. The therapy, under the brand name LYTENAVA™ (bevacizumab gamma), has received Marketing Authorization from the European Commission and the UK's MHRA for the treatment of wet AMD. The monoclonal antibody works by inhibiting vascular endothelial growth factor (VEGF).

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2025-10-03 English
PRIMARY DOCUMENT
Director's Dealing
2025-10-03 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text mentions a press release about a meeting with the FDA and plans to resubmit a biologics license application. It includes no detailed financial statements or comprehensive financial data. The document is relatively short (4095 characters) and primarily serves as an announcement of an event rather than a full report. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories.
2025-09-29 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 5, 2025. It reports the departure of a Chief Commercial Officer, Mr. Jeff Evanson, effective immediately. The content focuses on management changes, severance arrangements, and references to employment agreements and proxy statements. There are no financial statements or detailed financial data presented. The document is a current report on a material event, specifically a management change, which aligns with the category for announcements of changes in the company's board of directors or senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 4399 characters, which is typical for an 8-K filing on management changes and not a full annual or quarterly report.
2025-09-05 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The text includes a press release about the FDA issuing a complete response letter regarding a biologics license application. The document is relatively short (3794 characters) and primarily serves as an announcement of this event, including a press release as an exhibit. There are no detailed financial statements or comprehensive financial data presented. Therefore, this is not an Annual Report, Earnings Release, or Interim Report. It is a regulatory filing reporting a significant event, fitting the category of Regulatory Filings (RNS).
2025-09-02 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-14 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.